Cipla cuts prices of 3 cancer drugs by up to 64 pct

Thu Nov 8, 2012 1:18pm IST

Related Topics

Stocks

   

REUTERS - Drugmaker Cipla (CIPL.NS) cut prices of three cancer drugs between 50 percent and 64 percent with immediate effect, after it announced similar price cuts for three drugs early this year.

Lung cancer drug Erlocip would cost 9,900 rupees for 30 tablets instead of 27,000 rupees earlier, while breast cancer treatment Docetax would be priced 1,650 rupees instead of 3,300 rupees, Cipla said in a statement on Thursday.

Cipla last month won a case against Roche Holding (ROG.VX), which accused the Indian company of infringing patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.

Capegard, another drug to treat metastatic colorectal and colon caner, would be priced 600 rupees for 10 tablets instead of 1,200 rupees, it said. (Reporting by Kaustubh Kulkarni and Manoj Dharra in Mumbai; Editing by Subhranshu Sahu)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Culling Plans

REUTERS SHOWCASE

Root Out 'Bad Apples'

Root Out 'Bad Apples'

RBI chief calls for cleaning up of banking system.  Full Article 

Android One

Android One

Google launches $105 Android One; eyes low-price smartphone boom.  Full Article 

India-Vietnam Ties

India-Vietnam Ties

India tightens Vietnam defence, oil ties ahead of China Xi's visit.  Full Article 

Cognizant Deal

Cognizant Deal

Cognizant to buy TriZetto for $2.7 billion to boost healthcare business  Full Article 

Inflation Eases

Inflation Eases

Aug WPI inflation eases to near five-year low of 3.74 percent  Full Article 

Kashmir Floods

Kashmir Floods

Disease threatens as Kashmir flood waters turn fetid  Full Article 

Hepatitis Drug

Hepatitis Drug

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others   Full Article 

Trade Deficit

Trade Deficit

Exports growth slows to 2.4 pct in August  Full Article 

Battle for Heineken

Battle for Heineken

Four generations on, Heineken family won't loosen grip  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage